silybin has been researched along with Pituitary ACTH Hypersecretion in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cassarino, MF; Lasio, G; Losa, M; Pecori Giraldi, F; Sesta, A | 1 |
| Reincke, M; Theodoropoulou, M | 1 |
| Buchfelder, M; Freiburger, L; Hausch, F; Kozany, C; Paez-Pereda, M; Riebold, M; Sattler, M; Stalla, GK | 1 |
1 review(s) available for silybin and Pituitary ACTH Hypersecretion
| Article | Year |
|---|---|
Tumor-Directed Therapeutic Targets in Cushing Disease.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents; Cabergoline; Clinical Trials as Topic; Corticotrophs; Humans; Pituitary ACTH Hypersecretion; Roscovitine; Silybin; Somatostatin; Treatment Outcome; Tretinoin | 2019 |
2 other study(ies) available for silybin and Pituitary ACTH Hypersecretion
| Article | Year |
|---|---|
Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Antineoplastic Agents; Dexamethasone; Humans; Pituitary ACTH Hypersecretion; Pro-Opiomelanocortin; Receptors, Glucocorticoid; Silybin | 2023 |
A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Allografts; Animals; Disease Models, Animal; Drug Resistance; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Mice; Pituitary ACTH Hypersecretion; Protein Folding; Receptors, Glucocorticoid; Silybin; Silymarin | 2015 |